ICON Public (NASDAQ:ICLR) Releases FY 2025 Earnings Guidance

ICON Public (NASDAQ:ICLR) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 13.000-15.000 for the period, compared to the consensus estimate of 14.200. The company issued revenue guidance of $8.1 billion-$8.7 billion, compared to the consensus revenue estimate of $8.4 billion.

ICON Public Price Performance

ICLR opened at $183.62 on Wednesday. ICON Public has a 1 year low of $179.50 and a 1 year high of $347.72. The firm has a market capitalization of $14.83 billion, a PE ratio of 19.27, a price-to-earnings-growth ratio of 1.86 and a beta of 1.19. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.26 and a quick ratio of 1.34. The business’s 50-day moving average is $200.78 and its two-hundred day moving average is $238.28.

ICON Public (NASDAQ:ICLR) last posted its earnings results on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, beating analysts’ consensus estimates of $3.41 by $0.01. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. The company had revenue of $2.04 billion during the quarter, compared to analysts’ expectations of $2.04 billion. Research analysts anticipate that ICON Public will post 13.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on ICLR shares. Truist Financial dropped their price objective on shares of ICON Public from $284.00 to $262.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Robert W. Baird cut their price target on ICON Public from $221.00 to $203.00 and set a “neutral” rating on the stock in a research report on Tuesday. JPMorgan Chase & Co. decreased their price objective on ICON Public from $280.00 to $265.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. Citigroup dropped their target price on ICON Public from $300.00 to $290.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Finally, Leerink Partners reissued an “outperform” rating and issued a $255.00 price target (down from $270.00) on shares of ICON Public in a report on Tuesday, November 19th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, ICON Public presently has an average rating of “Moderate Buy” and an average target price of $279.17.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.